Business & Finance
Cumberland Pharmaceuticals reports January to July 2021 financial results
11 August 2021 -

Cumberland Pharmaceuticals reports January to July 2021 financial results Cumberland Pharmaceuticals Inc (NASDAQ: CPIX), a US-based specialty pharmaceutical company, announced on Tuesday its financial results for January to July 2021.

During January to July 2021, the company reported revenues at USD19.6m compared to USD17.9m for the year-ago period.

The company reported net income of USD1.4m during January to July 2021 compared to a loss of USD2m for the same period in 2020.The firm posted earnings per share attributable to common shareholders from Continuing operations – basic and Discontinued operations – basic were USD0.02 and USD0.07 respectively compared to losses of USD0.23 and USD0.10 respectively for the year-ago period.

'Cumberland continued to face headwinds due to the pandemic, but we are fortunate to have a diversified product portfolio that helped us counter the negative effects on our business, said AJ Kazimi, Cumberland Pharmaceuticals chief executive officer. 'We have adjusted our strategies and reinvented the way we operate in order to support our customers and the patients who can benefit from the delivery of our medicines.'

Login
Username:

Password: